SCHEMBL3977652

SCHEMBL3977652

O=C(NNC(=O)c1occ(-c2ccccc2)c1-c1ccccc1)c1ccc(O)cc1O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.60
KMT2A Q03164 4/20 0.60
KDM4E B2RXH2 5/20 0.46
HTT P42858 3/20 0.46
LMNA P02545 2/20 0.46
ALDH1A1 P00352 4/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
MAPT P10636 3/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
GFER P55789 2/20 0.44
GAA P10253 2/20 0.44
POLB P06746 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ALOX5 P09917 1/20 0.43
USP2 O75604 2/20 0.41
KEAP1 Q14145 1/20 0.41
NFE2L2 Q16236 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3977724 0.83 NPC1 (0.50) MEN1KMT2AALDH1A1SMN1; SMN2MAPT
SCHEMBL3982429 0.81 TOP1 (0.44) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL3981613 0.81 CCNC (0.42) MEN1KMT2AALDH1A1SMN1; SMN2MAPT
SCHEMBL3983962 0.78 MEN1 (0.40) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL3982131 0.78 KMT2A (0.40) MEN1KMT2ALMNAALDH1A1NPC1
SCHEMBL3983192 0.78 ESR1 (0.41) MEN1KMT2AKDM4ELMNANPC1
SCHEMBL3973507 0.78 MEN1 (0.40) MEN1KMT2AALDH1A1SMN1; SMN2MAPT
SCHEMBL3981075 0.78 MEN1 (0.40) MEN1KMT2AKDM4EHTTLMNA
SCHEMBL3976756 0.78 ACLY (0.40) KDM4EALDH1A1NPC1RAB9ATDP1
SCHEMBL3976138 0.77 RAB9A (0.50) MEN1KMT2AHTTLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514452-B2 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD (JP) 2009-04-07 US disclosed
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-04 US disclosed
EP-1489077-A1 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same GLP1R, GCGR, GPR119 MEN1 1481/4885KMT2A 3459/4885KDM4E 2769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.